Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Cholangiocarcinoma
Supportive Care and Management of Complications in BTCs: A Multidisciplinary Team Approach
Cholangiocarcinoma
January 2023, Vol 13, No 1
At the 4th Annual Cholangiocarcinoma Summit, held on October 13-15, 2022, experts in the field of gastroenterology, interventional radiology, nursing, and surgery discussed the importance of using a multidisciplinary approach to supportive care and the management of complications in patients with biliary tract cancers (BTCs).
Read More ›
Imjudo, a New CTLA-4 Inhibitor, FDA Approved in Combination with Imfinzi for Unresectable HCC
FDA Approvals, News & Updates
,
Cholangiocarcinoma
January 2023, Vol 13, No 1
On
October 21, 2022
, the FDA approved tremelimumab (Imjudo; AstraZeneca), a CTLA-4 monoclonal antibody, in combination with durvalumab (Imfinzi; AstraZeneca), a PD-L1 inhibitor, for the treatment of adults with unresectable hepatocellular carcinoma (HCC).
Read More ›
2022 Year in Review: Cholangiocarcinoma
By
Richard Kim, MD
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
In 2022, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums. Adapting to the changes, societies such as the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, and European Society for Medical Oncology have adopted virtual and hybrid formats that deliver cutting-edge research in the advancement of oncology care. Recognizing the challenges of the virtual and hybrid formats in terms of reach and impact, we are bringing the
Year in Review
series that seeks to disseminate key information on treatment advances to clinicians in a timely and effective manner.
Read More ›
Durvalumab plus GemCis in Advanced BTC: A New Standard-of-Care?
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer.
Read More ›
Updated Results from the FOENIX-CCA2 Trial of Futibatinib in Patients with iCCA Harboring FGFR2 Fusions/Rearrangements
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring
FGFR2
fusions/rearrangements.
Read More ›
Results from the BilT-04 Study: First-Line GemCis with or without CPI-613 in Advanced BTCs
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
The BilT-04 study revealed that the addition of CPI-613 to gemcitabine/cisplatin was well-tolerated with potential activity in patients with advanced biliary tract cancers.
Read More ›
Final Results from the FIGHT-202 Trial of Pemigatinib in Metastatic CCA
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
Final analysis of the phase 2 FIGHT-202 trial demonstrated durable response and a tolerable safety profile for pemigatinib in patients with metastatic cholangiocarcinoma.
Read More ›
Updated Results from the TOPAZ-1 Study of Durvalumab plus GemCis in Patients with Advanced BTC
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
Updated data from the TOPAZ-1 study revealed improved median overall survival for the full patient population and no new safety signals.
Read More ›
TOPAZ-1 Trial Subanalysis: Outcomes by Primary Tumor Location in Advanced BTCs
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
Subanalysis of the phase 3 TOPAZ-1 trial found that durvalumab plus gemcitabine/cisplatin showed efficacy as a treatment regimen in patients with biliary tract cancer regardless of primary tumor location.
Read More ›
Early Data from the ReFocus Trial
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
Early data from the ReFocus trial indicated that RLY-4008 may be an effective new treatment for patients with cholangiocarcinoma harboring
FGFR2
fusions or rearrangements.
Read More ›
Page 1 of 5
1
2
3
4
5
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Out Models Cost Patients and Employers More Than They Disclose
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
By
Marianne Davies, DNP, ACNP, AOCNP, FAAN
;
Shawn Perkins, RN, BSN, OCN
3.
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma
By
William King
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes